| Talquetamab studied in …STUDIED_INderived38 of 38show fewer |
|---|
| → studied in | NCT05050097Phase 1 · active not recruiting A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03399799Phase 1 · active not recruiting Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108195Phase 1 · active not recruiting A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04634552Phase 2 · recruiting A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05338775Phase 1 · active not recruiting A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455320Phase 3 · active not recruiting A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552222Phase 3 · recruiting A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208150Phase 3 · active not recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06500884Phase 2 · recruiting A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06550895Phase 2 · active not recruiting A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577025Phase 2 · active not recruiting A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06827860Phase 2 · recruiting Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06572605Phase 1/Phase 2 · suspended External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740486Phase 3 · not yet recruiting A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07720843Phase 1 · not yet recruiting TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855121recruiting The Norwegian Immunotherapy in Multiple Myeloma Study · 38 trials list this drug (32 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia,AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06461988Phase 2 · recruiting Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649525Phase 3 · recruiting Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level · 38 trials list this drug (32 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07657312Phase 2 · recruiting Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06993675Phase 2 · recruiting Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05849610Phase 2 · active not recruiting Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma · 38 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05972135Phase 2 · recruiting Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07107529Phase 2 · recruiting Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07032714Phase 1 · recruiting Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07499323NA · not yet recruiting Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · 38 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353022Phase 2 · active not recruiting Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06348108Phase 1 · recruiting Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03601078Phase 2 · completed An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06066346Phase 2 · recruiting A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06100237Phase 2 · recruiting Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04586426Phase 1/Phase 2 · active not recruiting A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07093554Phase 1 · recruiting Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05695508Phase 2 · recruiting GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05503550no longer available Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05757973approved for marketing Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04773522Phase 1 · completed A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05461209Phase 3 · withdrawn A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma · 38 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06505369Phase 2 · recruiting Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients · 38 trials list this drug (32 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |